Ampersand — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
AnaBiosanabios.comin𝕏May 2022
AnaBios generates predictive human data for pharmaceutical drug development, using authentic human cells and tissues from healthy and diseased donors to assess drug efficacy and toxicity before clinical trials.
BiotechDeep TechHealthtechSan Diego
Andre Ghetti(Executive Officer, Director)Richard F. Erdman(Director)Paul Miller(Executive Officer)Jack Reynolds(Executive Officer, Director)Peter Crowley(Director)George Goldsmith(Director)
Co-investorsKeiretsu Forum
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.